OVIT — OncoVista Innovative Therapies Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $1.54m
Annual income statement for OncoVista Innovative Therapies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2010 December 31st | 2011 December 31st | 2012 December 31st | 2013 December 31st | 2014 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1.88 | 2.2 | 1.87 | 1.52 | 2.55 |
Operating Profit | -1.88 | -2.2 | -1.87 | -1.52 | -2.55 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.29 | -2.23 | -1.63 | -1.45 | -2.54 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2.29 | -2.23 | -1.63 | -1.45 | -2.54 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 10.1 | -2.03 | -1.63 | -1.45 | -2.54 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 10.1 | -2.03 | -1.63 | -1.45 | -2.54 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.137 | -0.105 | -0.081 | -0.067 | -0.118 |
Dividends per Share |